Search Medical Condition
Please enter condition
Please choose location

Eastbourne, United Kingdom Clinical Trials

A listing of Eastbourne, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial

STAMPEDE (also known as MRC PR08) is a multi-arm multi-stage (MAMS) randomised controlled trial recruiting in the UK and Switzerland. It aims to evaluate multiple therapeutic strategies in the management of high-risk locally advanced and metastatic hormone-naïve prostate cancer. Each novel treatment strategy is compared against a single, contemporaneous control ...

Phase

0.0 miles

Learn More »

Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

OBJECTIVES: Primary - Compare the efficacy and toxicity of single-agent irinotecan hydrochloride (Ir) vs Ir with cyclosporine (IrC) in patients with fluorouracil-resistant advanced colorectal cancer. - Compare the efficacy of single-agent Ir vs Ir with panitumumab (IrP) in these patients. Secondary - Correlate the toxicity of Ir and/or IrC with ...

Phase

1.56 miles

Learn More »

Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer

OBJECTIVES: - Determine the safety and efficacy of conventional vs hypofractionated high-dose intensity-modulated radiotherapy in patients with localized prostate cancer. - Determine the side effects of these regimens in these patients. - Determine whether hypofractionated radiotherapy schedules will improve the therapeutic ratio by either improving tumor control or reducing normal ...

Phase

1.56 miles

Learn More »

Eastbourne Syncope Assessment Study II

The original EaSyAS study (1998) evaluated the use of implantable loop recorders (ILRs) in the diagnosis and management of syncope.This demonstrated a significant increase in successful diagnosis following use of implantable loop recorders. Here there were 442 syncope admissions to Eastbourne in 2001. Diagnostic rate was 42%. In addition, time ...

Phase N/A

1.56 miles

Learn More »

Registry to Evaluate the ROX COUPLER in Patients With Resistant or Uncontrolled Hypertension

The purpose of this registry is to evaluate the safety and performance of the ROX COUPLER in patients with treatment-resistant or uncontrolled hypertension.

Phase

1.56 miles

Learn More »

Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer

OBJECTIVES: Primary - Determine disease-free survival of women with HER2-positive early breast cancer treated with neoadjuvant or adjuvant trastuzumab (Herceptin®) for 6 months versus 12 months. Secondary - Determine the overall survival of patients treated with these regimens. - Determine the expected incremental cost effectiveness (cost per quality adjusted life ...

Phase

1.56 miles

Learn More »

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage) Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

This multicenter study uses a randomized, double-blind, placebo-controlled, parallel-group design. A screening period (SCR) running up to 10 weeks before randomization will be used to assess subject eligibility followed by 104 weeks of treatment. At BSL approximately 990 subjects whose eligibility is confirmed will be randomized to one of four ...

Phase

1.56 miles

Learn More »

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.

Phase

8.08 miles

Learn More »

A Phase III Parallel Group Study Comparing the Efficacy Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA® dry powder inhaler (DPI) is being developed by GlaxoSmithKline (GSK) with the aim of providing a new treatment option for the management of asthma by improving lung function, health-related quality of life (HRQoL) and symptom control over established ...

Phase

9.51 miles

Learn More »

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

9.88 miles

Learn More »